Heron Therapeutics | HRTX - Current Liabilities


Heron Therapeutics reported $96.1M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
ALKERMES USD 599.5M 56.06M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
ANI Pharmaceuticals USD 278.11M 7.56M Dec/2025
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 347.42M 151.94M Dec/2025
Eisai JPY 387.67B 9.42B Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Surmodics USD 19.44M 1.1M Jun/2025
Ultragenyx Pharmaceutical USD 384M 43.98M Dec/2025
Veracyte USD 59.94M 12.22M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026